Arkolith/Insider Trading/KDNY/Form 4

King Andrew James

Chief Scientific OfficerCHINOOK THERAPEUTICS, INC. (KDNY) · full profile →Form 4 · filed Aug 11, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
14
1 non-derivative · 13 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 11, 2023Disposed to issuer(D)19K——0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Aug 11, 2023Disposed to issuer(D)10K——0
Aug 11, 2023Disposed to issuer(D)60K$24.86$1.5M0
Aug 11, 2023Disposed to issuer(D)90K$25.23$2.3M0
Aug 11, 2023Disposed to issuer(D)73K$39.58$2.9M0
Aug 11, 2023Disposed to issuer(D)43K$39.65$1.7M0
Aug 11, 2023Disposed to issuer(D)8K——0
Aug 11, 2023Disposed to issuer(D)26K——0
Aug 11, 2023Disposed to issuer(D)7K——0
Aug 11, 2023Disposed to issuer(D)100K$27.10$2.7M0
Aug 11, 2023Disposed to issuer(D)104K$14.73$1.5M0
Aug 11, 2023Disposed to issuer(D)22K$22.41$482K0
Aug 11, 2023Disposed to issuer(D)7K——0
Aug 11, 2023Disposed to issuer(D)17K——0

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-23-045424) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML